Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Names Alacris CSP for Target Enrichment

NEW YORK (GenomeWeb) – Agilent Technologies today said it named Alacris Theranostics an Agilent Certified Service Provider for target enrichment. 

Alacris is based in Berlin and provides molecular analysis and bioinformatics through an approach called ModCell, which is intended to match patients with appropriate therapies. According to Agilent, Alacris exploits next-generation sequencing and other omics data to facilitate drug development and personalized medicine in cancer and other complex diseases. 

ModCell was developed at the Max Planck Institute for Molecular Genetics and is exclusively licensed to Alacris. 

For its CSP program, Agilent chooses companies that will leverage Agilent's technologies in providing analysis services. Agilent trains the firms on its workflow to ensure that customers receive consistent data quality, reproducibility, and reliability, it said. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.